Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
This article was originally published in The Pink Sheet Daily
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
You may also be interested in...
Aveo’s Tivozanib Will Face Challenging Survival Data At ODAC Review
FDA’s Oncologic Drugs Advisory Committee will consider the tyrosine kinase inhibitor for advanced renal cell carcinoma at a May 2 meeting. Aveo has attributed a negative overall survival trend in the TIVO-1 study to a crossover design and use of post-progression therapies among patients randomized to the comparator arm.
Preparing For Tivozanib Approval, Aveo Restructures With Staff Cuts
The Cambridge, Mass.-based company slows R&D and lays off 17% of its work force, but prepares to build a sales staff as it continues to reap auspicious data on the kidney cancer drug.
2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.